{"entity":{"id":"nct07407803","kind":"trial","name":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","aka":[],"tldr":"A phase 3 trial testing TQ-B3234 in rare cancers of childhood, now recruiting.","summary":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas is a phase 3 interventional study registered as NCT07407803, led by Chia Tai Tianqing Pharmaceutical, and recruiting on the registry. Official title: Randomised, Double-Blind, Parallel-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQ-B3234 Capsules Versus Placebo in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas. Planned enrolment is 177 participants (estimated). The study started in 2026-03-31 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07407803","url":"https://clinicaltrials.gov/study/NCT07407803"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rare-childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":["tq-b3234"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07407803","phase":"3","setting":"Randomized, Double-Blind, Parallel-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of TQ-B3234 Capsules Versus Placebo in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","sponsor":"Chia Tai Tianqing Pharmaceutical","participation":[{"nct":"NCT07407803","source":"https://clinicaltrials.gov/study/NCT07407803","fetchedAt":"2026-10-07T16:55:43.582Z","studySha256":"8b69d868360cc00dc61d1fabdc94f73e81c36ed9b788a5fa45506855ed69355f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-27","leadSponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":177,"enrolmentType":"ESTIMATED","siteCount":29,"recruitingSiteCount":3,"countries":["China"]}],"started":"2026-03-31","startedType":"actual","enrolled":177,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07407803/","neighbours":{"cancer":[{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/"}],"drug":[{"id":"tq-b3234","kind":"drug","name":"TQ-B3234","route":"/drugs/tq-b3234/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}